06.33The United States adds 248,429 deaths and 11,340,563 infections from Covid-19The United States reached the figure of 11,340,563 confirmed cases of the SARS-CoV-2 coronavirus on Tuesday and 248,429 deaths from the covid-19 disease, according to the independent count from Johns Hopkins University. This balance at 20.00 local time (01.00 GMT on Wednesday) is 1,313 more deaths than Monday and 149,952 new infections. Despite the fact that New York is no longer the state with the highest number of infections, it remains the worst hit in terms of deaths in the United States with 34,076. It is followed in number of deaths by Texas (20,147), California (18,312), Florida (17,644) and New Jersey (16,618). Other states with a large death toll are Illinois (11,317), Massachusetts (10,360), Pennsylvania (9,346), Georgia (9,008) or Michigan (8,511).
06.24Argentina totals 1.32 million positives of covid-19 and 36,106 deathsArgentina added 10,621 new infections of the SARS-CoV-2 coronavirus this Tuesday, so the infections amounted to 1,329,005, while the covid-19 has already left 36,106 deaths, after 379 deaths have been reported in the last 24 hours. The Argentine Ministry of Health reported that the province of Buenos Aires remains the district with the most confirmed cases so far (594,248, of which 2,804 were notified this Tuesday), followed by the country’s capital, with 154,596 confirmed positives, 428 of them reported today. Behind them is the central province of Santa Fe, which this Tuesday added 1,477 cases and accumulates 130,929 of them since the start of the pandemic. 06.16Chinese Covid-19 Vaccine Candidate Appears ‘Safe’, Study FindsThe formulation of a Chinese COVID-19 vaccine candidate appears “safe” and induces an antibody response in healthy volunteers aged 18 to 59, according to preliminary results of a study published Tuesday in The Lancet. The findings come from a randomized clinical trial of a vaccine – “CoronaVac” – based on the inactivated SARS-CoV-2 virus and reveal that antibody responses could be induced within 28 days of the first immunization, administering two doses of the vaccine 14 days apart. The research, carried out by a Chinese team, identifies the optimal dose with which to generate the highest immune responses while taking note of side effects.